The initial public offering (IPO) of the pharmaceutical company Corona Remedies is off to a slow start on the first day of its subscription on December 8, 2025. Valued at ₹655.37 crore, the public offering comprises an entirely offer-for-sale (OFS) with promoters and shareholders divesting up to 6.2 million equity shares.